UK markets close in 7 hours 56 minutes

Kiromic BioPharma, Inc. (KRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2614-0.0026 (-0.98%)
At close: 03:35PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.2640
Open0.2508
Bid0.0000 x 1000
Ask0.0000 x 1800
Day's range0.2500 - 0.2699
52-week range0.2300 - 2.3800
Volume121,222
Avg. volume664,187
Market cap4.77M
Beta (5Y monthly)-0.10
PE ratio (TTM)N/A
EPS (TTM)-2.1820
Earnings date12 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Kiromic BioPharma Arranges Up to $10 Million Financing

    HOUSTON, October 27, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, LTD, a partnership managed by Yorkville Advisors Global LP, a global investment manager, to sell up to $8 mi

  • Business Wire

    Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy

    HOUSTON, October 06, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it received validating written feedback on October 4, 2022 from the FDA pursuant to its Type B Pre-IND meeting request regarding its Deltacel™ development strategy.

  • Business Wire

    Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer

    HOUSTON, July 12, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the appointment of Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately. Dr. Mirandola has served as the Company’s Vice President of Research & Development and Clinic